How to take Panitumumab

Panitumumab is a human monoclonal antibody EGFR antagonist that can be used as a single agent for metastatic colorectal cancer that has progressed after treatment with fluoropyrimidine, oxaliplatin, and irinotecan chemotherapy regimens. It can also be used in combination with FOLFOX. Before patients started treatment with panitumumab, the RAS mutation status of their colorectal tumors was assessed and the absence of RAS mutations in exon 2 (codons 12 and 13), exon 3 (codons 59 and 61), and exon 4 (codons 117 and 146) of KRAS and NRAS was confirmed.

The recommended dose of panitumumab is 6 mg/kg as a 60-minute intravenous infusion every 14 days. If the first infusion is tolerated, give subsequent infusions over 30-60 minutes, giving doses exceeding 1000 mg over 90 minutes. If a patient experiences a mild or moderate (Grade 1 or 2) infusion reaction during the infusion, the physician will reduce the infusion rate by 50%. Patients who experience severe infusion reactions should have their infusion discontinued and, depending on the severity and/or persistence of the reaction, panitumumab should be permanently discontinued. Panitumumab is not indicated for the treatment of patients with RAS-mutant mCRC or patients whose RAS mutation status is unknown.

It is understood that the original version of panitumumab has not yet been launched in China, and therefore it has not been covered by medical insurance. The price of the Hong Kong original version of panitumumab sold in Hong Kong, China100mg/5mL may be around RMB 9,000 (the price may fluctuate due to exchange rates). There are currently no generic drugs of Panitumumab on the market. If a patient has a need to purchase Panitumumab, please consult a medical consultant for specific prices and more drug information.